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Human coronaviruses (HCoV) mainly cause common cold-like symptoms. However, 
in the last two decades the emerging coronaviruses the severe acute respiratory 
syndrome coronavirus (SARS-CoV) (in 2002), Middle East respiratory syndrome 
coronavirus (MERS-CoV) (in 2014) and SARS-CoV-2 (in 2019) were introduced into 
the human population from animal reservoirs and were found to cause severe 
disease. Novel antiviral strategies are required to combat these viruses particularly 
the pandemic SARS-CoV-2, the causative agent of coronavirus disease 2019 
(COVID-19). Coronaviruses harbor a spike glycoprotein (S) in their envelope, which 
is responsible for host cell entry. Entry depends on S protein interactions with cellular 
receptors and on S protein activation by host cell proteases. The goal of this thesis 
was to identify these interaction partners and to characterize these interactions on 
the molecular level, with the ultimate goal to identify targets for antiviral intervention. 
The thesis work revealed that MERS-CoV and SARS-CoV-2 S proteins depend on 
furin-mediated cleavage at the so called S1/S2 site for subsequent S protein 
cleavage at the S2’ site, which results in S protein activation for entry into human 
lung cells. Moreover, the results of this thesis show that polymorphisms in the S 
protein of MERS-CoV can protect the virus against antibody mediated neutralization 
and that polymorphisms in the viral receptor dipeptidyl peptidase 4 (DPP4), modulate 
entry efficiency. Finally, it was uncovered that SARS-CoV-2, like SARS-CoV, 
employs angiotensin-converting enzyme 2 (ACE2) and the transmembrane serine 
protease subtype 2 (TMPRSS2) for entry into lung cells and evidence was provided 
that the clinically proven TMPRSS2 inhibitor camostat mesylate could be used for 
COVID-19 treatment. In sum, the study provided key insights into host cell entry of 
MERS-CoV and SARS-CoV-2 and defined TMPRSS2 as target for intervention.  





Humane Coronaviren (HCoV) führen in den meisten Fällen zu Erkältungen. 
Allerdings sind in den letzten zwei Jahrzenten neuartige Coronaviren, severe acute 
respiratory syndrome coronavirus (SARS-CoV) (2002), Middle East respiratory 
syndrome coronavirus (MERS-CoV) (2014) and SARS-CoV-2 (2019) von Tieren auf 
den Menschen übergesprungen und verursachen schwere Erkrankungen. Um diese 
Viren, besonders das pandemische SARS-CoV-2 und die daraus resultierende 
Krankheit coronavirus disease 2019 (COVID-19) zu bekämpfen werden neue 
antivirale Strategien benötigt. Coronaviren tragen auf ihrer Hülle ein Spike (S) 
Glykoprotein, welches für den zellulären Eintritt verantwortlich ist. Der Eintritt beruht 
auf der Interaktion des S Proteins mit dem zellulären Rezeptor und der Aktivierung 
des S Proteins durch Wirtszellproteasen. Das Ziel dieser Arbeit war es diese 
Interaktionspartner zu identifizieren und die Interaktion auf einem molekularen Level 
zu charakterisieren, um neue Targets für antivirale Strategien zu finden. Diese Arbeit 
hat ergeben, dass MERS-CoV und SARS-CoV-2 S Proteine für die Spaltung an der 
S2‘ Schnittstelle, zunächst auf die Furin-vermittelte Spaltung an der S1/S2 
Schnittstelle angewiesen sind. Dies führt zu der Aktivierung der S Proteine für den 
Eintritt in humane Lungenzellen. Des Weiteren konnte in dieser Arbeit gezeigt 
werden, dass Polymorphismen in dem S Protein von MERS-CoV das Virus vor 
Antikörper-vermittelter Neutralisation schützen und dass Polymorphismen in dem 
viralen Rezeptor Dipeptidyl-pepdiase 4 (DPP4) die Eintrittseffizienz verändern. Zum 
Schluss wurde entdeckt, dass SARS-CoV-2, wie SARS-CoV, Angiotensin-
konvertierendes Enzyme 2 (angiotensin-converrting enzyme 2 (ACE2)) und die 
Transmembrane Serine Protease Subtype 2 (TMPRSS2) für den Eintritt in humane 
Lungenzellen benötigt. Darüber hinaus wurde der Nachweis erbracht, dass der 
klinisch geprüfte TMPRSS2 Inhibitor Camostat mesylate für die Behandlung von 




COVID-19 Patienten verwendet werden kann. Zusammengefasst liefert diese Arbeit 
wichtige Ergebnisse bezüglich des zellulären Eintritts von MERS-CoV und SARS-
CoV-2 und definiert TMPRSS2 als Ziel für antivirale Interventionen.  
 





Coronaviruses (family Coronaviridae) are enveloped viruses of animals and humans 
that, depending on the virus and host species, can cause mild to severe diseases. In 
total seven human coronaviruses (HCoV) have been identified so far, HCoV-NL63 
(Fouchier et al., 2004; Van Der Hoek et al., 2004) and HCoV-229E (Hamre and 
Procknow, 1962), which belong to the Alphacoronavirus genus and HCoV-OC43 
(McIntosh et al., 1967), HCoV-HKU1 (Woo et al., 2005), severe acute respiratory 
syndrome coronavirus (SARS-CoV) (Drosten et al., 2003; Peiris et al., 2003), SARS-
CoV-2 (Gorbalenya et al., 2020; Wang et al., 2020; Zhu et al., 2020) and Middle East 
respiratory syndrome coronavirus (MERS-CoV) (Zaki et al., 2012), which belong to 
Betacoronavirus genus. HCoV-229E, OC43, HKU-1 and NL63 circulate worldwide 
and cause the common cold. Before 2002, HCoV were believed to only cause mild, 
common cold-like disease in otherwise healthy adults but this perception changed. In 
2002 an outbreak and subsequent epidemic spread of a novel lung disease, severe 
acute respiratory syndrome (SARS), occurred in China. SARS was caused by SARS-
CoV, which was transmitted from civet cats to humans (Drosten et al., 2003; Peiris et 
al., 2003; De Wit et al., 2016).SARS-CoV infections were reported until May 2004 
(WHO, 2004). Roughly ten years later, the emergence of a new lung disease, Middle 
East respiratory syndrome (MERS) caused by another novel coronavirus was 
observed in the Middle East in 2012. The causative agent MERS-CoV was first 
detected in the Kingdom of Saudi Arabia (KSA) and is transmitted from dromedary 
camels to humans (Zaki et al., 2012; Mohd, Al-Tawfiq and Memish, 2016). 
Coronaviruses can also be found in livestock and companion as well as wild animals. 
In livestock and companion animals different coronaviruses have been identified, 
which affected animal health and thus can lead to economic losses due to reduced 
productivity of livestock: Transmissible gastroenteritis virus (TGEV) and porcine 




epidemic diarrhea virus (PEDV) in pigs, bovine coronavirus (BCoV) in cattle; 
infectious bronchitis virus (IBV) in poultry and feline enteric coronavirus (FCoV) which 
can mutate and become the highly virulent variant feline infectious peritonitis virus 
(FIPV) (Fehr and Perlman, 2015). In case of MERS-CoV, dromedary camels and 
bats are the most relevant animal species harboring coronaviruses. Dromedaries 
were, as mentioned before identified as the natural reservoir of MERS-CoV and 
represent the main source of human infections (Azhar et al., 2014; Reusken et al., 
2016; Alshukairi et al., 2018; Conzade et al., 2018). In bats, several coronaviruses 
were identified e.g. BatCoV-HKU4 and BatCoV-HKU5, which belong to the lineage C 
of the genus Betacoronavirus and are closely related to MERS-CoV. (Woo et al., 
2012; Lau et al., 2013). As of May,13th, the pandemic SARS-CoV-2 has infected over 
four million people worldwide and more than 280,000 deaths can be attributed to the 
associated severe respiratory illness coronavirus disease 2019 (COVID-19) (WHO, 
2020). One factor important for the pandemic potential of SARS-CoV-2 is the high 
transmissibility between humans (Shereen et al., 2020). In comparison to SARS-
CoV-2 human-to-human transmission of SARS-CoV and MERS-CoV is less efficient. 
Nevertheless, MERS-CoV has been introduced into 27 countries via air travel, led to 
large hospital outbreaks (e.g. in 2015 in the Republic of Korea) and new cases are 
constantly emerging in the Middle East (Anderson et al., 2004; Memish et al., 2013; 
Drosten et al., 2014; Ki, 2015; Mackay and Arden, 2015). Dromedary camels were 
identified as the natural reservoir of MERS-CoV. The prevalence in dromedary 
camels in the Middle East and in Africa is around 90 % (Reusken et al., 2013, 2014; 
Alagaili et al., 2014; Alexandersen et al., 2014; Chu et al., 2014; Memish, Cotten, 
Meyer, et al., 2014). MERS-CoV belongs to the lineage C of the genus 
Betacoronavirus, and MERS-CoV isolates can be further classified into two major 
clades, A and B (Lau et al., 2017). Clade A contains a total of five virus strains, 




including the first isolate of MERS-CoV (human betacoronavirus 2c EMC/2012) (Lau 
et al., 2017). Clade B includes most MERS-CoV strains including those isolated 
during the outbreak in the Republic of Korea in 2015 (Lau et al., 2017). Furthermore, 
MERS-CoV isolates found in Africa form into a separate group, clade C (D. Chu et 
al., 2018). In order to group MERS-CoV strains into the different clades the amino 
acid (aa) residues at position 1020 in the viral spike glycoprotein is of importance. 
While for clade A MERS-CoV this position contains a glutamine (Q1020),clade B 
MERS-CoV harbor an arginine residue (R1020) (Lau et al., 2017).  
 
3.1. Biology and replication 
3.1.1. MERS biology and classification 
Coronaviruses are positive single stranded (+ss) RNA viruses and belong to the 
family Coronaviridae. Together with Arteriviridae, and Roniviridae they form the order 
Nidovirales. Furthermore, the family Coronaviridae can be divided in the two 
subfamilies Coronavirinae and Torovirinae, and among the subfamily Coronavirinae 
four genera, Alpha-, Beta-, Gamma- and Deltacoronavirus were defined (Gorbalenya 
et al., 2006; de Groot et al., 2012). Alpha- and betacoronaviruses primarily infect 
mammals, while gamma- and deltacoronaviruses mainly infect birds (Nakagawa, 
Lokugamage and Makino, 2016). Coronaviruses in general cause mild lower 
respiratory tract infections and gastrointestinal symptoms (Gorbalenya et al., 2006; 
Van Der Hoek, 2007). The zoonotic human coronaviruses, SARS-CoV, MERS-CoV 
and SARS-CoV-2, belong to the group Betacoronavirus, which is divided into the 
different lineages A, B and C. MERS-CoV belongs to lineage C and can be further 
classified into different clades (Lau et al., 2013, 2017), while SARS-CoV and SARS-
CoV-2 belong to lineage B (Cascella et al., 2020). 




The coronavirus virion has a spherical shape and a diameter of 120-160nm. In 
electron microscopy, all virions show 20nm long club-shaped projection from the 
outer envelope, which are representing spike (S) protein trimers. Those projections 
resemble a “crown” (lat. Corona), which is the origin for the virus name. All members 
of the family Coronaviridae harbor the membrane glycoprotein (M), the envelope (E) 
glycoprotein and the S protein, which share similarities in size and structure, thereby 
giving evidence of a common ancestor. Especially the S protein has a domain 
organization: signal peptide (SP), receptor binding domain (RBD), fusion peptide 
(FP), heptad repeats 1 and 2 (HR1 und HR2) and the transmembrane domain (TD). 
Moreover, the betacoronaviruses of the lineage A harbor a membrane anchored 
hemagglutinin-esterase (HE) (Gorbalenya et al., 2006; Bakkers et al., 2017). The 
positive +ss RNA genome of coronaviruses is associated with the viral nucleoprotein 
(N) and contained inside the virion as a helical nucleocapsid with 9-11nm in 
diameter. The genome is non-segmented, capped at the 5’-end and harbors a 
polyadenylated 3’-end. Coronaviruses have the largest genome of all RNA viruses 
with a size of 27-32 kb and ten open reading frames (ORF). MERS-CoV and SARS-
CoV-2 have 30119 and 29891 nucleotide large genomes, respectively. The ORF1a 
and ORF1b encode for two thirds of the viral genome and include 16 non-structural 
proteins (nsp), which are required for synthesis of viral proteins and viral genome 
replication. The remaining nine ORFs encode for the structural proteins (S, M, E, N) 
and for further nsps, 3, 4a, 4b, 5 8b with largely unknown function (Almazán et al., 
2013; Boheemen, Graaf and Lauber, 2013; Scobey et al., 2013; Cascella et al., 
2020).  
 




3.1.2. MERS replication cycle 
The MERS-CoV replication cycle starts with the binding of the virus to the surface of 
the host cell. Binding is mediated by the S protein, which interacts with the cellular 
receptor dipeptidyl peptidase 4 (DPP4) via its receptor binding domain (RBD). After 
receptor binding the S protein fuses the viral membrane with a target cell membrane 
allowing delivery of the viral genome into the host cell. Membrane fusion requires 
cleavage of the S protein by host cell proteases, which activates the S protein, as 
discussed in detail later (Taguchi et al., 1995; Fehr and Perlman, 2015). The 
translation of the replicase proteins, based on the viral RNA, is the next step of the 
replication cycle. The replicase proteins are encoded by the two large ORFs, ORF1a 
and ORF1b, which encode for two polyproteins, pp1a and pp1b, respectively. These 
polyproteins are cleaved into individual nsps by a virus encoded protease (Brierley, 
Digard and Inglis, 1989; Ziebuhr, Snijder and Gorbalenya, 2000; Sawicki, Sawicki 
and Siddell, 2007). MERS-CoV, like other coronaviruses, expresses two cysteine 
proteases (papain-like proteases (PLpros) and the main protease (Mpro)), which are 
necessary for expression of mature viral proteins and viral pathogenesis (Malik and 
Alsenaidy, 2017). The PLpros cleaves nsp1/2, nsp2/3 and nsp3/4, while the other 
boundaries are cleaved by Mpro. The suitable environment for RNA synthesis, 
including the RNA replication and transcription of sub-genomic RNAs, is provided by 
the assembly of nsps into the replicase-transcriptase complex. Besides its function to 
form the replicase-transcriptase complex the nsps contain other enzymatic functions 
important for RNA replication (Fehr and Perlman, 2015). The synthesis produces 
genomic and sub-genomic RNAs, where the sub-genomic RNAs serve as messenger 
RNAs (mRNA) for the structural and accessory genes (Sethna, Hofmann and Brian, 
1991). This is followed by the translation of the structural proteins (S, E and M) and 
there insertion into the endoplasmatic reticulum (ER). The structural proteins move 




along the secretory pathway into the ER-Golgi-intermediate compartment (ERGIC). 
At the ERGIC the viral genomes are encapsidated by N and virions bud into the 
ERGIC membrane where mature virions are produced. The virions are transported to 
the cell membrane and released by exocytosis (de Haan and Rottier, 2005; Durai et 
al., 2015a; Fehr and Perlman, 2015; Zumla et al., 2015).   




Table 1: Function of coronavirus non-structural proteins (nsp). 
The table shows the indicated coronavirus nsps with their known function. The table has been adapted 
from (Fehr and Perlman, 2015) 
Non-structural Protein (nsp) Function 
nsp1 blocks host innate immune response 
nsp2 unknown 
nsp3 
interacts with N Protein, promotes 
cytokine expression, cleaves viral 
polyproteins and blocks host innate 
immune response 
nsp4 
potential transmembrane scaffold 
protein 
nsp5 encodes for the main protease (Mpro) 
nsp6 
potential transmembrane scaffold 
protein 
nsp7 forms hexadecameric complex with nsp8 
nsp8 forms hexadecameric complex with nsp7 
nsp9 RNA binding protein 
nsp10 
cofactor for nsp16 and nsp14, forms 
heterodimer with both and stimulates 




encodes the RNA-dependent RNA 
polymerase (RdRp) domain 
nsp13 
encodes the RNA helicase domain and 
RNA 5′-triphosphatase activity 
nsp14 
encodes the ExoN involved in replication 
fidelity and N7-methyltransferase activity 
nsp15 
encodes endoribonuclease (NendoU) 
activity 
nsp16 
encodes 2′-O- methyltransferase activity 
blocking immune response 





Figure 1: MERS-CoV replication cycle.  
1) The viral spike (S) protein binds to the host cell receptor dipeptidyl peptidase 4 (DPP4) which, leads 
to the release of the viral RNA into the cellular cytoplasm. 2) The two large open reading frames 
(ORF), ORF1a, ORF1b are translated into the polyproteins pp1a and pp1ab, respectively, which are 
cleaved by the virus encoded proteases (papain-like protease (PLpro)) into non-structural proteins 
(nsps). 3) The proteins necessary for replication accumulate in double membrane vesicles (DMV) 
derived from the endoplasmic reticulum (ER). 4) During RNA synthesis discontinued subgenomic RNA 
and full-length RNA for replication are synthesized. 5) The newly synthesized RNA is encapsidated in 
the nucleoprotein (N) in the cytosol, transported to the ER-Golgi intermediate compartment (ERGIC) 
for assembly. The S, membrane (M) and envelope (E) proteins are inserted into the membrane of the 
ER and transported to the ERGIC where progeny virions are assembled. 6) Vesicles containing virions 
are transported to the plasma membrane and released by exocytosis. 7) During viral replication 
double-stranded (ds) RNAs are generated. The 4a competes with the retinoic acid-inducible gene I 
(RIG-I) to bind the dsRNA and evades the host immune response. The figure is adapted from (Durai et 
al., 2015b). 




3.2. MERS-CoV zoonosis 
MERS-CoV is zoonotically transmitted to humans (Zaki et al., 2012). Dromedary 
camels have been identified as natural reservoir of MERS-CoV. The seroprevalence 
between dromedary camels is around 90%, including camels in the Middle East and 
Africa (Sikkema et al., 2019). However human cases are only reported from the 
Middle East. It is unclear why the virus was able to cross the species barrier in the 
Middle East but not in Africa (Reusken et al., 2013, 2014; Alexandersen et al., 2014; 
Chu et al., 2014; Memish, Cotten, Meyer, et al., 2014; Meyer et al., 2014; Müller et 
al., 2014; Mohd, Al-Tawfiq and Memish, 2016).  
Primary transmission of MERS-CoV between dromedaries and humans occurs via 
close contact or consumption of row camel meat (Müller et al., 2015). Most cases of 
human-to-human transmission are detected in hospitals between the index person 
and its relatives or the medical staff. Several major hospital outbreaks of MERS have 
been reported, including a hospital outbreak in the Republic of Korea in 2015, which 
involved 186 causes and 36 deaths and was caused by a single infected person who 
traveled from the Middle East to the Republic of Korea (Khan et al., 2015; Ki, 2015). 
MERS-CoV infections have been detected in 27 different countries. MERS-CoV 
infections are detected in many countries in the Arabian Peninsula but were also 
detected in Europe or the USA. The introduction in other countries outside the 
Arabian Peninsula is mainly possible due to air travel.  
  




3.2.1. Incubation period and symptoms 
Normally HCoV cause mild, common cold like respiratory symptoms. Typical 
symptoms of MERS-CoV infection are coughing, shortness of breath often 
associated with non-specific signs like fatigue, myalgia fever, and headache 
Furthermore, MERS-CoV infections can also be associated with gastrointestinal 
symptoms like vomiting and diarrhea. In severe cases, MERS-CoV infection leads to 
atypical pneumonia, renal failure or multiorgan failure. The median incubation period 
of MERS is roughly five days (Bermingham et al., 2012; Guery et al., 2013; Omrani et 
al., 2013; Memish, Cotten, Watson, et al., 2014; Rabeeah et al., 2014; Tsiodras et 
al., 2014; Zhou et al., 2017). Moreover different studies have shown that females and 
males are equally affected and MERS patients can be found at all ages. Severe 
cases of MERS-CoV infections might be detected in patients with comorbidities: 
hypertension, diabetes mellitus, renal or cardiovascular disease, obesity, smoking, 
lung disease like cystic fibrosis and asthma or patients with immunosuppression 
(Guery et al., 2013; Al-Tawfiq and Memish, 2014; Memish, Cotten, Watson, et al., 
2014; Rabeeah et al., 2014; Oboha et al., 2017).  
  




3.2.2. Korea outbreak 
The pandemic potential of MERS-CoV is highlighted by several major hospital 
outbreaks. The outbreak in the Republic of Korea in 2015 was the largest hospital 
outbreak. The outbreak was caused by one single infected person (68-year old man), 
who traveled from the Middle East to the Republic of Korea (Khan et al., 2015). The 
outbreak involved three cycles of human-to-human transmission and was due to 
insufficient safety measurement, travel of patients between hospitals and crowed 
patients rooms (Choi, 2015; Khan et al., 2015; Ki, 2015; Lee and Wong, 2015; 
Mizumoto et al., 2015). Further spread of the virus was prevented by isolation of 
patients with unknown respiratory disease, visitation routines and improvement of 
hygiene routines in public hospital, e.g. disinfection and hand-washing (Khan et al., 
2015; Jeon and Kim, 2016). Notably, the MERS outbreak in Korea encompassed 
transmission of viral variants with mutations in the S protein that reduced 
neutralization of virus by antibodies, providing evidence that the virus can evolve to 
evade immune control in humans. 
  




3.3. Structural proteins of MERS-CoV 
MERS-CoV particles contain four structural proteins, which have different functions: 
E, M, N and S (de Haan and Rottier, 2005) (Figure 2A). E is encoded by all 
coronaviruses but only few copies of the protein are incorporated into the viral 
envelope (Kuo and Masters, 2003). A deletion of the E protein can lead to a blockade 
of virus maturation, decreasing virus release and spread (Fischer et al., 1998; Wilson 
et al., 2004). The E protein belongs to the group of viroporins. Viroporins form ion 
channels in the virion envelope and thereby modify membrane permeability. 
Furthermore, the E protein can affect the release of progeny virions from infected 
cells by modifying the plasma membrane (Gonzalez and Carrasco, 2003). The E 
protein of MERS-CoV is involved in ion channel activity as virulence factor and 
thereby could be a potential drug target (Yang et al., 2013). The M protein is also 
incorporated into the viral envelope protein and controls most protein-protein 
interactions required for assembly of coronaviruses. In case of MERS-CoV, M was 
hypothesized to be an interferon (IFN) antagonist (Yang et al., 2013). The N-terminus 
of the M protein is located outside of the particle whereas the C-termini is directed to 
the virus interior (Escors, Camafeita, et al., 2001; Escors, Ortego, et al., 2001). The N 
protein is associated with the viral genome to form the nucleocapsid and can 
modulate sub-genomic RNA synthesis and genome replication (Almazan, Galan and 
Enjuanes, 2004; Schelle et al., 2005). The MERS-CoV N protein was shown to 
suppress the type I and type II IFN (Chang et al., 2020). As in all coronavirus, the 
trimers of the viral S protein are inserted into the viral membrane and facilitate entry 
into target cells, as described in detail (Lu et al., 2013; Wang et al., 2013; Li, 2015). 
 





Figure 2: Schematic MERS-CoV particle. 
MERS-CoV particles include the four structural 
proteins: trimeric Spike (S) protein (blue), 
membrane (M) protein (orange), envelope (E) 
protein (purple), the nucleocapsid (N) (red) and 
the RNA (gray) are labeled (Xu et al., 2019). 




3.3.1. The MERS-CoV spike protein: Domain organization and entry reaction 
The MERS-CoV-S protein (MERS-S) mediates viral entry into target cells. For this, 
the S protein binds to its host cell receptor, DPP4, and fuses the viral membrane with 
the cellular membrane. Receptor binding and membrane fusion are mediated by 
different subunits of MERS-S. The subunit 1 (S1) contains the RBD, which binds to 
DPP4, while the transmembrane subunit 2 (S2) harbors the functional elements 
required for membrane fusion (Drosten et al., 2003; Gao et al., 2013; Raj et al., 2013; 
Wang et al., 2013; Lu et al., 2014). The RBD harbors the receptor binding motif 
(RBM) that directly contacts DPP4, and a core subdomain. The RBD spans from aa 
367 to 606, the RBM itself from aa 484 to 567. The core subdomain of the RBD is 
composed of a five stranded antiparallel betasheet and several connecting alpha 
helices, stabilized by sulfate bonds. The RBM is divided into a four-stranded 
antiparallel betasheet connected via intervening loops (Chen et al., 2013; Lu et al., 
2013; Wang et al., 2013). The S2 subunit contains HR1 and HR2, the FP and the TD 
(Figure 4A), functional elements that are also found in glycoproteins of other viruses 
that all mediate membrane fusion in a similar fashion and are termed class I 
membrane fusions. Membrane fusion commences with insertion of the MERS-S 
fusion peptide into the target cell membrane. Next, the HR1 and HR2 fold back onto 
each other and from a six-helix-bundle (6HB), thereby bringing the viral and host cell 
membrane in close proximity for the following membrane fusion (Figure 4B) (Gao et 
al., 2013; Lu et al., 2014). Finally, MERS-S-driven host cell entry critically depends 
on S protein cleavage between the S1 and S2 subunits, termed S1/S2 and a 
cleavage site located directly upstream of the fusion peptide (S2’) (Figure 4A) and 
both sites need to be cleavage for entry, as discussed below (Gierer et al., 2013; 
Qian, Dominguez and Holmes, 2013; Shirato, Kawase and Matsuyama, 2013; Millet 
and Whittaker, 2014).  







Figure 3: Spike protein structure. 
(A) The MERS-CoV-S (MERS-S) contains a surface subunit (S1) and a transmembrane subunit 
(S2).The S1 subunit harbor the signal peptide (SP) and the receptor binding domain (RBD), which 
directly interacts with the host cell receptor DPP4. The S2 subunit harbors the fusion peptide (FP), the 
heptad repeat 1 (HR1) and 2 (HR2), the transmembrane domain (TM) and the cytoplasmic tail (CT). 
MERS-S harbors three cleavage sites for host cell proteases: The S1/S2 cleavage site is located at 
the border of the S1 and the S2 subunit, the S2’ cleavage site is located directly upstream of the FP 
and a cathepsin B/L cleavage site (ECP, endosomal cathepsin proteases) is proposed to be located 
between the S1/S2 and S2’ site. (B) Membrane fusion driven by MERS-S. The binding of the S protein 
to the host cell receptor DPP4 triggers a conformational change, resulting in the formation of a pre-
hairpin intermediate structure, in which the fusion peptide (red) is introduced into the target cell 
membrane. The pre-hairpin intermediate folds into stabilized trimer of hairpins, called the six helix 
bundle structure (6HB). This leads to the close proximity of the target cell membrane and the viral 
envelope and thereby to membrane fusion. The figure is adapted from (Kleine-Weber et al., 2018; Xu 
et al., 2019) 
(A) 
(B) 




3.3.2. Crystal structure of MERS-S 
Single particle cryo-electron microscopy was used to resolve the crystal structure of 
MERS-S trimers. Two different conformations were detected regarding the RBD, 
which can either be “standing” or “laying” (Yuan et al., 2017). Trimers of MERS-S 
with one or two out of three RBDs in a standing position were observed. It was 
hypothesized that the conformational state with all three RBDs in a standing position 
was not detected due to easy dissociation of the S1 trimer form the S2 component 
(Yuan et al., 2017). Apart from the flexible RBDs the rest of the trimeric structure 
remained stable. The S1 subunit includes the N-terminal domain (NTD) and two 
additional domains which form the base of a hairpin structure with the RBD/NTD ring 
complex on top (Yuan et al., 2017). The NTD harbors the binding site for cellular 
glycans e.g. sialic acids (Li et al., 2017). The dynamic characters of the RBDs 
enables the interaction with the host cell receptor as it is only exposed during the 
“standing” state while in the “laying” state the residues are buried inside the trimer. It 
was hypothesized that the dimeric DPP4 may cross-link two trimeric S proteins by 
binding two standing RBDs from different trimers S proteins (Yuan et al., 2017).  
 
Figure 4: Spike protein crystal structure. 
The crystal structure of the trimeric spike protein in a side view and a top view is shown. The residues 
of the receptor binding domain (RBD) are colored in red. The protein model was constructed on the 
published crystal structure (5X59) deposited in RSCB PDB.  




3.4. MERS-S protein interaction with DPP4 
The viral S-driven host cell entry relies as mentioned before on the binding of the S 
protein with the host cell receptor DPP4. The interface of these proteins is known. 15 
amino acid residues in DPP4 bind to 14 amino acid residues in MERS-S (Raj et al., 
2013; Wang et al., 2013).  
 
 
Figure 5: Polymorphic amino acid residues in DPP4 at the binding interface with MERS-S. 
In the DPP4 close-up all interacting residues are labeled with possible polymorphisms and the 
interacting MERS-S residue. The non-polymorphic sides are marked in blue. The polymorphic 
residues are labeled and marked in green. The protein model was constructed on the published 
crystal structure (4PV7) deposited in RSCB PDB.  
 




3.4.1. Biological function of host cell factors required for MERS-CoV entry 
3.4.1.1. Dipeptidyl-peptidase 4 (DPP4) 
The host cell receptor needed for the S protein driven host cell entry is DPP4 
(DPPIV, CD26, also known as adenosine deaminase binding protein). It was 
originally described in 1966 by Hopsu-Havu and Glenner (Hopsu-Havu and Glenner, 
1966; Hopsu-Havu, Jansén and Järvinen, 1970; Raj et al., 2013). DPP4 is a serine 
protease with the unique ability to cleave a peptide bond. It preferentially cleaves 
dipeptides of the free N-terminus when proline or alanine is present. DPP4 is a type II 
membrane protein with various tissue expression, while it is most abundant in kidney 
and the small intestine (Darmoul et al., no date; Walter and Post-proline, 1978; 
Kettmann, Humbel and Holzhausen, 1992; Tanaka et al., 1992; Zhou et al., 2017). It 
was further found at ciliated and non-ciliated cells in the airways but was more often 
observed with higher levels in small airways. However, DPP4 was rarely observed in 
the epithelial of nasal mucosa, which could influence the infection of the lower 
airways by MERS-CoV (Vliegen et al., 2017). Even if DPP4 is classified as a 
membrane protein it is also active in its soluble form found in bone marrow, 
adipocytes skeletal muscle and vascular smooth muscle cells (Lamers et al., 2011; 
Raschke et al., 2013; Röhrborn, Eckel and Sell, 2014; Wang et al., 2014).  
The primary structure of DPP4 is composed of a six aa long cytoplasmic tail, 22 aa 
transmembrane domain and 738 aa extracellular domain. The extracellular portion 
includes a flexible stalk, a glycosylation-rich region, a cysteine-rich region and a 
catalytic domain which comprises the catalytic residues Ser630, Asp708 and His740. 
DPP4 is a homodimer and is anchored in the membrane by its signal peptide 
(Weihofen et al., 2004; Chung et al., 2010). Each monomer can be divided into two 
domains: the eight blade propeller and the alpha/beta-hydrolase. The propeller 
domain can be further divided into subdomains which consist of blade II to V for the 




glycosylation-rich region or VI to VIII for the cysteine-rich region (De Meester et al., 
1999; Lambeir et al., 2003; Gorrell, 2005). The two main regions important for 
binding with the S protein are located within blade V and VI. The soluble form of 
DPP4 only misses the CT and the TD, so that it is not membrane anchored anymore 
but still has all catalytic domains and thereby is still active (Klemann et al., 2016; 
Peck et al., 2017).  
In general DPP4 is involved in many different physiological processes: the immune 
response by T-cell activation with binding to caveolin-1 or adenosine deaminase 
(ADA) which both bind to the glycosylation-rich region, the cell adhesion by binding 
extracellular matrix molecules like fibronectin which interacts with the cysteine-rich 
region, the degradation into and assimilation of proline containing peptides and the 
glucose metabolism, by degradation of insulinotropic peptides (Kameoka et al., 1993; 
De Meester et al., 1994, 1999; Lambeir et al., 2003; Demuth, McIntosh and 
Pederson, 2005; Gorrell, 2005). DPP4 is important for the body homeostasis for 
example Diabetes mellitus can occur depending on the disruption of the glucose 
metabolisms. DPP4 cleaves the incretins glucagon-like peptide 1 (GLP1) and the 
gastric inhibitory polypeptide (GIP) respectively glucose-dependent insulinotropic 
peptide. These enzymes are responsible for the insulin secretion when intact glucose 
is present. Both have a half-time of a few minutes and are degraded strictly 
depended on DPP4 activity (Pederson et al., 1998; Yasuda et al., 2002; Conarello et 
al., 2003; Demuth, McIntosh and Pederson, 2005). Furthermore diabetes is 
comorbidity for MERS-CoV infections as well as obesity, smoking or lung disease like 
asthma and cystic fibrosis. It was shown that soluble DPP4 is upregulated in the lung 
epithelia of smokers and patients with lung disease which could increase MERS-CoV 
infection (Assiri, Al-Tawfiq, et al., 2013; Assiri, McGeer, et al., 2013; Al-Tawfiq et al., 




2014; Memish, Al-Tawfiq, et al., 2014; Al-abdallat et al., 2016; Meyerholz, Lambertz 
and McCray, 2016; Seys et al., 2018).  
 
3.4.1.2. Sialic acids 
Sialic acids are monosaccharide’s which are expressed at the surface of all 
eukaryotic cells and can cap oligosaccharides on N and O linked glycoprotein’s or 
glycolipids (Varki, 2009). Furthermore glycans terminating in sialic acids serve as 
class of receptors for many different viruses. Sialic acids can be cleaved from the 
glycan sequences on the host cells by neuraminidase which can inhibit viral spread. 
Α-5-N-acetyl-neuraminic-acid (Neu5Ac) is the most common structure of sialic acids. 
It can bind to the hemagglutinin (HA) of influenza virus A and B (Sauter et al., 1992; 
Wang et al., 2007; Gamblin and Skehel, 2010; Viswanathan et al., 2010) and the HE 
of the BCoV (Zeng et al., 2008). The MERS-S protein provides a dual binding site for 
the host cell receptor DPP4 and sialic acids via distinct domains. DPP4 interacts with 
the RBM in the S1 subunit and sialoglycans can bind in the first part of the S1 subunit 
between aa 18-355. In case of MERS-CoV, the expression of sialoglycans is not 
sufficient for host cell entry but they can serve as an attachment receptor and can 
increase viral entry in presence of DPP4. Finally, MERS-S is highly selective for the 
Neu5Ac variant of sialic acids (Li et al., 2017).  
 
3.4.2. Host cell proteases 
MERS-S needs to be proteolytic primed by host cell proteases for efficient host cell 
entry. Proprotein convertases (PPC), serine proteases or cysteine cathepsins can 
activate MERS-S and may cleave it at two distinct sites, S1/S2 or S2’.  




3.4.2.1. Proprotein Convertases (PPC) 
PPC are endoproteolytic processing enzymes of the secretory pathway in humans 
(Steiner, 1998). In general newly synthesized proteins are inactive precursor proteins 
which need to be proteolytically activated. This precursor cleavage can be mediated 
by PPC and mainly occurs at a multibasic cleavage site (also known as multibasic 
motif): R/K –Xn-R/K ↓. The Xn marks an undefined number of any aa. and PPC’s 
cleave after the second R/K residue indicated by the arrow (Seidah and Chretien, 
1999). In 1989 furin was the first discovered PPC (Fuller, Brake and Thorner, 1989). 
It is one of the main proteases necessary for the proteolytic activation of MERS-S. 
The cleavage motif of furin is more stringent. The motif: R-X-R/K-R ↓, starts and ends 
with an arginine. In between are only two aa located, one undefined and the second 
needs to be an arginine or lysine. However the furin cleavage is further influenced by 
other aa in close proximity to the cleavage motif. In general, not all cleavage sites 
contain the furin specific cleavage motif and not all sites that include the specific 
motif are cleaved by furin due to the further characteristics. Furin has a preference 
for basic arginine (R) or lysine (K) residues at P3, P5 and P6. P1’ and P2’ are 
characterized by the absence of lysine residues, while P1’ preferentially include aa’s 
with polar or negatively charged side chains. All these positions influence the 
cleavage (Nakayama, 1997; Henrich et al., 2003). In MERS-S the S1/S2 as well as 
the S2’ cleavage site can be processed by furin. In contrast to SARS-CoV, SARS-
CoV-2 harbors a multibasic motif and might proteolytically activated by furin cleavage 
(Millet and Whittaker, 2014; Hoffmann, Kleine-Weber, et al., 2020). PPC’s are 
involved in a large variety of protein activation like peptide hormones, growth and 
differentiation factors, adhesion factors, receptors, extracellular matrix proteins and 
exogenous proteins e.g. coat glycoprotein’s of virus particles. It was shown 




previously that furin is able to cleave the glycoprotein of human immunodeficiency 
virus 1 (HIV-1) and influence A virus (IAV) (Duckert, Brunak and Blom, 2004).  
 
3.4.2.2. Type II transmembrane serine proteases 
Type II transmembrane serine proteases (TTSPs) are expressed in all vertebrates. 
Transmembrane serine protease subtype 2 (TMPRSS2) can be found in epithelial of 
gastrointestinal, urogenital and respiratory tracts (Vaarala et al., 2001). TMPRSS2 
plays an essential role for activation of HCoV because the host cell entry of HCoV 
including HCoV-OC43, HCoV-HKU1, HCoV-229E, SARS-CoV, MERS-CoV and 
SARS-CoV-2 is mediated via the cell surface pathway (Szabo and Bugge, 2008; 
Kawase et al., 2012; Shirato, Kawase and Matsuyama, 2018a; Hoffmann, Kleine-
Weber, et al., 2020). TTSPs are composed of different N-terminal transmembrane 
domains, a C-terminal extracellular serine protease domain which contains the 
catalytic histidine, aspartic acid and serine domains and a stem region. TTSPs can 
be divided into four different classes: HAT/DESC, hepsin/TMPRSS, matripase and 
corin. TMPRSS2 belongs to the second family, the hepsin/TPMRSS class. The 
specificity of this class is a group A scavenger domain in its stem region, proceed by 
a low-density-lipoprotein receptor class A domain in TMPRSS2/3/4. TTSPs are 
synthesized as inactive precursor proteins, which need to be activated by cleavage. 
Even after activation these proteins remain membrane anchored due to a disulfide 
bond that links the prodomain and the catalytic domain (Hooper et al., 2001; Szabo 
and Bugge, 2008). The main function of TTSPs is to stabilize the basic homeostasis 
rather than re-establish it after external challenging like infections. Furthermore they 
are involved in growth factor activation or initiation of proteolytic cascades (Bugge, 
Antalis and Wu, 2009). TMPRSS2 itself was found in the basal epithelium of the 
prostate epithelium and later in the epithelial cells of kidney, upper airways, alveoli 




and ovaries. TMPRSS2 is proposed to regulate epithelial sodium currents in the lung 
via proteolytic cleavage of sodium channels and to regulate inflammatory response in 
the prostate (Lin et al., 1999; Afar et al., 2001; Donaldson et al., 2002; Wilson et al., 
2005). In the context of IAV infection it was shown that TMPRSS2 knock-out (KO) 
mice exhibited a decreased viral spread and increased survival rates. However 
TMPRSS2 KO mice did not show any phenotype by which the physiological role 
remains unclear (Bugge, Antalis and Wu, 2009; Hatesuer et al., 2013). TMPRSS2 is 
expressed in many cells in the respiratory tract which may drive virus infection of IAV 
and SARS-CoV shown to be activated by TMPRSS2 (Glowacka et al., 2011; Bertram 
et al., 2012). Furthermore, TMPRSS2 is able to activate MERS-S at the S2’ site. The 
cleavage by TMPRSS2 relies on the presence of a monobasic arginine motif. In case 
of TMPRSS2 a monobasic motif preferentially at P1 is sufficient for cleavage in 
contrast to furin, which requires a multibasic motif (Kleine-Weber et al., 2018).  
Camostat mesylate is a serine protease inhibitor, which blocks the activity of 
TMPRSS2. Treatment of cells with TMPRSS2 was shown to block MERS-CoV, 
SARS-CoV and IAV replication (Kawase et al., 2012; Shirato, Kawase and 
Matsuyama, 2013; Yamaya et al., 2015; Hoffmann, Kleine-Weber, et al., 2020). 
  




3.4.2.3. Cysteine cathepsins 
Cathepsins are proteases that are active in a slightly acidic environment. Besides the 
cysteine cathepsins to which e.g. cathepsins B, L, V, K belong, two other major 
cathepsin groups are described which are the serine and aspartic protease 
cathepsins (Turk et al., 2012). Most cysteine cathepsins including cathepsin L 
(CTSL) are ubiquitously expressed in human tissue. However, it was shown that in 
human lung cells (e.g. Calu-3) CTSL isles expressed compared to TMPRSS2 (Park 
et al., 2016). Cysteine cathepsins are active in slightly acidic environment and are 
unstable at neutral pH, thus they are intracellular proteases involved in degradation 
of intra- and extracellular proteins (Turk et al., 2012). Furthermore, CTSL was shown 
to be involved in the endosomal proteolytic activation of the S protein of MERS-CoV 
(Gierer et al., 2013; Park et al., 2016).  
Cathepsin activity can be blocked by different compounds. MDL28170 a cathepsin B 
(CTSB) and CTSL inhibitor can reduce the EBOV-GP driven host cell entry and was 
also shown to act in blocking the S-driven host cell entry of SARS-CoV and MERS-
CoV (Afar et al., 2001; Kawase et al., 2012; Gierer et al., 2013; Hoffmann et al., 
2019). Ammonium chloride (NH4Cl) elevates the endosomal pH and mediates 
inhibition of cathepsins by disrupting the acidic environment needed for activation of 
cathepsins. Thus, ammonium chloride treatment could inhibited the SARS-S-driven 
host cell entry (Simmons et al., 2005). 
  




3.5. The novel emerging Coronavirus - SARS-CoV-2 
In December 2019, a novel betacoronavirus SARS-CoV-2, emerged in the city of 
Wuhan, Hubei region in China. SARS-CoV-2 is phylogenetically-related to SARS-
CoV, which has caused the SARS pandemic 2002/2003. While SARS-CoV was 
transmitted from civet cats to humans, the animal spillover host for SARS-CoV-2 
remains to be identified (Guan et al., 2003; De Wit et al., 2016; Zhu et al., 2020). 
Similar to SARS-CoV, SARS-CoV-2 employs the angiotensin-converting enzyme 2 
(ACE2) as host cell receptor and the viral S protein can be proteolytic primed by 
TMPRSS2 (Li et al., 2004; Hoffmann, Kleine-Weber, et al., 2020). The 
carboxypeptidase ACE2 is a type I integral membrane protease expressed in various 
tissues like kidney, endothelium, lung and heart. ACE2 is further involved in the 
renin-angiotensin system (RAS), which itself is necessary for the regulation of 
homeostasis of the vascular functions (Donoghue et al., 2000; Tipnis et al., 2000; 
Crowley et al., 2005; Tikellis and Thomas, 2012). Infection of humans with SARS-
CoV-2 can lead to the disease COVID-19, that can manifest itself as self-limiting, 
common cold like disease with, fever and coughing. However, also development of 
severe, life-threatening pneumonia is possible and it is believed that severe disease 
might correlate with increased age and pre-existing comorbidities, like diabetes, 
respiratory diseases and/ or obesity (Guo et al., 2020). The median incubation period 
of SARS-CoV-2 infection is five to six days and thus equally to incubation periods 
observed for MERS-CoV (Guan et al., 2020; Guo et al., 2020). Different to SARS-
CoV and MERS-CoV, SARS-CoV-2 can be transmitted with high efficiency between 
humans. Through trading and air travel, SARS-CoV-2 has been introduced into 
countries worldwide, resulting in a pandemic (Anderson et al., 2004; Mackay and 
Arden, 2015; Shereen et al., 2020). The pandemic spread of COVID-19 highlights the 
urgent need for specific antiviral treatment options and vaccines against 




coronaviruses. Until today, no antiviral therapeutic or vaccine is licensed for 
treatment of coronavirus infections in humans.  
 
3.6. Animal models and therapeutic targets 
The most efficient prevention of virus infections including coronaviruses is 
vaccination. Vaccines are available for a few animal coronaviruses including IBV and 
TGEV. But those vaccines cannot be used permanently because of lack of efficiency 
or recombination events. In case of MERS-CoV no vaccine is licensed for humans or 
for camels. However, two vaccines candidates entered clinical trials for use in 
humans (GLS-5300 and MERS0001). In addition another candidate has been tested 
in dromedary camels for human or veterinary use (modified vaccinia virus Ankara 
(MVA) vector to express MERS-S) (Xu et al., 2019).Therapeutic targets for the 
tretament could be for example the S protein, accessory proteins, DPP4 or host cell 
proteases. The S protein can be targeted at the RBD or NTD via neutralizing 
antibodies. Here, monoclonal antibodies targeting residues close to the interacting 
sites were proven most efficient (Wang et al., 2015, 2018). JC57-14 (non-human 
primate (NHP)) and F11 (mice) are two of those monoclonal RBD-specific antibodies. 
JC57-14 interacts with S protein residue W535 and F11 interacting with S protein 
residue D509, both were able to show neutralizing potential. However, for both 
antibodies escape mutations were observed (Wang et al., 2018). The accessory 
protein 4a was shown to target the host IFN response; the blocking of this function by 
anti-viral therapeutics could inhibit viral spread (Niemeyer et al., 2013). The host cell 
receptor DPP4 is important for viral entry. Besides the S protein, DPP4 can bind to 
other cellular factors at the cell surface like ADA. ADA is a cofactor for DPP4 which 
can antagonize the S protein binding by blocking DPP4 (Raj et al., 2014). 
Furthermore the host cell proteases are necessary for entry: Furin, TMPRSS2 and 




CTSL are necessary for the viral activation. Those proteases can also be used as 
therapeutic targets. TMPRSS2 can be blocked efficiently by camostat mesylate and 
CTSL by the inhibitor MDL28170, both compounds were shown to inhibit MERS-S 
driven host cell entry in cell culture (Gierer et al., 2013; Shirato, Kawase and 
Matsuyama, 2013). However, MDL28170 was shown to introduce rapid mutations 
which lead to resistance of VSV-EBOV to MDL28170 (Hoffmann et al., 2019). All 
compounds shown to be affective in vitro still need to be tested in vivo.  
Animal models are necessary to prove the effect of vaccines and therapeutics. For 
MERS-CoV different animal models were established. Rhesus macaques were the 
first established animal model. The animals were permissive for viral infection and 
showed acute transient, moderate respiratory disease with coughing and fever (De 
Wit et al., 2013; Falzarano et al., 2013; Munster, de Wit and Feldmann, 2013; 
Falzarano, Wit, et al., 2014; Yao et al., 2014). Another animal model is common 
marmosets, which develop a severe respiratory disease that rapidly becomes lethal. 
The respiratory and immune system of common marmosets and rhesus macaques is 
similar to humans, which is an advantage for confirming vaccines and antiviral 
therapeutics (Falzarano, de Wit, et al., 2014). Nevertheless, mouse models were also 
developed for MERS-CoV, but to be efficient they need to be DPP4 transduced or 
transgenic DPP4 mice. The advantage of mice models is that they are easy to handle 
and useful for screening. However, mice develop other symptoms than humans and 
transgenic mice present a global overexpression of DPP4 (Baseler, de Wit and 
Feldmann, 2016). The ongoing SARS-CoV-2 pandemic shows the urgency for 
treatment options of coronaviruses. Therefore already approved antiviral therapeutics 
are tested for the treatment for COVID-19 patients. Nevertheless, the need for 






MERS-CoV can cause a life-threatening pneumonia in humans and has pandemic 
potential. The general potential of emerging coronaviruses to cause pandemics is 
presently demonstrated by the ongoing COVID-19 pandemic. While MERS-CoV can 
be transmitted from dromedary camels to humans, also for SARS-CoV-2 it is very 
likely that initial human infections occurred via close contact with an (at present 
unknown) infected animal. The coronaviral S protein mediates viral entry into target 
cells and is a viral key determinant that defines the range of susceptible host species 
and cell types. The S protein engages specific cellular receptors and, upon 
proteolytic activation (priming) by cellular proteases, induces fusion of the viral and 
cellular membranes thereby delivering the viral genome into the cell. The underlying 
virus-host-cell-interactions are crucial for viral entry and thus might serve as targets 
for antiviral therapy. Therefore two central questions were addressed in this thesis: 
 
1) Which host cell factors are required for the cellular entry driven by MERS-S? In 
detail, are there cell type-specific protease requirements with respect to the S1/S2 
and S2’ cleavage sites. Further, do naturally occurring polymorphisms in the 
MERS-CoV cell receptor DPP4 or MERS-S itself impact the viral entry efficiency?  
 
2) Which host cell factors are crucial for the host cell entry of SARS-CoV-2? In 
particular, is the S protein of SARS-CoV-2 also primed by TMPRSS2 and can 
TMPRSS2 thus be a therapeutic target? 
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MERS-CoV and SARS-CoV-2 pose a severe threat to human health. Both 
coronaviruses have a zoonotic origin and recently spilled over into the human 
population. MERS-CoV emerged in 2012 in the KSA and, since then, has been 
sporadically transmitted from dromedary camels to humans with only limited local 
spread mainly restricted to the Middle-East (Mackay and Arden, 2015; Killerby et al., 
2020). In contrast, SARS-CoV-2 infections have been first noticed in the winter of 
2019 the city of Wuhan in China from where the virus has subsequently been 
disseminated all over the world causing an ongoing pandemic with more than four 
million infections and over 280,000 deaths (WHO, 2020). This work demonstrates, 
that MERS-CoV and SARS-CoV-2 share striking commonalities with respect to 
proteolytic priming of their respective surface glycoprotein, S protein, a step that is 
crucial for viral entry into target cells of the human lung. 
The investigation and in-depth understanding of the host cell entry process, including 
virus attachment to host cells trough interaction of the viral S protein and its cellular 
receptor molecule as well as the proteolytic priming of the S protein by host cell 
proteases provide the basis for the development of antiviral intervention strategies 
(Gao et al., 2013; Du et al., 2017).  
Transduction vectors like vesicular stomatitis virus-based pseudotype particles 
bearing coronavirus S proteins faithfully mirror the cellular entry process of 
coronaviruses and thus provide a save platform to study S-driven host cell entry in 
absence of the infectious authentic coronavirus and are thus powerful toll to study the 
early events of the viral lifecycle (Tani, Morikawa and Matsuura, 2012).  




6.1. Functional characterization of host cell factors required for cellular 
entry driven by the S protein of MERS-CoV 
6.1.1. Analysis of molecular requirements for S protein priming revels cell 
type specific priming strategies for MERS-S 
MERS-S harbors two multibasic cleavage sites, the S1/S2 and the S2’ sites, that are 
important for proteolytic priming and thus viral entry into target cells, I could 
demonstrate that the requirement for proteolytic priming as the MERS-S S1/S2 site is 
cell type dependent while priming at the S2’ site is universally required for S protein 
activation. Thus the viral entry driven by a mutant MERS-S variant was strongly 
reduced for TMPRSS2-positive Caco-2 cells, while entry into TMPRSS2-negative 
Vero cells was at the same level as for wildtype MERS-S. In contrast, mutation of the 
S2’ site in MERS-S caused decreased S protein-driven cellular entry for all cell lines 
tested (Kleine-Weber et al., 2018). It is now generally believed that a pre-priming 
event at the S1/S2 site is mediated by the PPC furin during S protein transport along 
the secretory pathway in the infected cell (Gierer et al., 2013), which enables a 
second priming event at the S2’ site that is performed by TMPRSS2 after attachment 
to new target cells (Park et al., 2016; Kleine-Weber et al., 2018). MERS-S further 
harbors an additional cleavage site for CTSL near the S1/S2 site, which was shown 
to be required for S protein priming within endosomal vesicles after endocytosis of 
receptor-bound virus in TMPRSS2-negative cells (Gierer et al., 2013; Yang et al., 
2015; Park et al., 2016; Kleine-Weber et al., 2018). In this context, a study by Yang 
and coworkers showed that introduction of a glycosylation site at the CTSL priming 
site in MERS-S severely attenuated S protein-driven host cell entry (Yang et al., 
2015)  




However, the role of CTSL-mediated MERS-S priming is controversially discussed 
and there are several lines of evidence, which suggest that it might represent a cell 
culture adaptation and has no biological relevance in vivo. In contrast, S protein 
priming by TMPRSS2 seems to be crucial for cellular entry driven by the S protein of 
MERS-CoV and other coronaviruses in vivo. TMPRSS2 is known to play a crucial 
role in activation of S proteins of related coronaviruses such as SARS-CoV or HCoV-
229E, as well as the HA of several IAV strains (Ebara, Fukuda and Saisho, 2003; 
Hatesuer et al., 2013; Shirato, Kawase and Matsuyama, 2013, 2018b; Zmora et al., 
2015; Shirato et al., 2016). Further, it is reported that clinical isolates of HCoV-229E, 
HCoV-OC43 and HCoV-HKU1 preferentially enter human cells following S protein 
priming through TMPRSS2, while the CTSL-mediated S protein priming was mainly 
observed for viruses that have been previously passaged in cell culture (Shirato et 
al., 2016; Shirato, Kawase and Matsuyama, 2018a). With respect to the availability of 
CTSL and TMPRSS2 for priming of coronavirus S proteins in the human lung cells, a 
study by Park and colleagues demonstrated that CTSL expression in these cells is 
low, while TMPRSS2 expression is high (Park et al., 2016). The latter finding could 
further be confirmed and extended to the lung as a whole organ by my own work 
(Kleine-Weber et al., 2018). Lack of in vivo relevance for CTSL-mediated S protein 
priming has been demonstrated by Zhou and colleagues, who showed that treatment 
of SARS-CoV infected mice with a CTSL inhibitor did not protect from fatal disease (9 
out of 10 succumbed to infection), while inhibition of serine proteases like TMPRSS2 
by administration of camostat mesylate allowed 6/10 mice to survive (Zhou et al., 
2020).  
 




Given the overwhelming scientific evidence, which indicates that TMPRSS2 is the 
main activating protease of the S proteins of HCoV in the human lung a major focus 
of my work was dedicated to the in-depth analysis of TMPRSS2-mediated MERS-S 
priming.  
Similar to trypsin, TMPRSS2 requires only a single basic amino acid residue 
(arginine or lysine) for the cleavage of polypeptides (Hooper et al., 2001; Szabo and 
Bugge, 2008). Using a mutational approach, in which I exchanged individual or 
multiple arginine residues by alanine residues, I could show that the S2’ site is a 
substrate for TMPRSS2-mediated MERS-S priming (Kleine-Weber et al., 2018). 
Moreover, I found out that only the second arginine (R887) of the multibasic motif at 
the S2’ site of MERS-S is crucial for efficient S protein priming by TMPRSS2 (Kleine-
Weber et al., 2018). With respect to the MERS-S S1/S2 priming site I further 
demonstrated that removal of either of the two arginine residues abolished MERS-S 
pre-priming and, as a consequence, abrogates subsequent MERS-S priming by 
TMPRSS2 and thus S protein-driven entry into TMPRSS2-positive target cells. It can 
thus be concluded that the MERS-S S1/S2 site is cleaved by proteases that require a 
multibasic motif e.g. furin, while the S2’ site is a substrate for proteases that can 
cleave at a monobasic motif e.g. TMPRSS2 (Fuller, Brake and Thorner, 1989; 
Seidah and Chretien, 1999; Yang et al., 2014; Kleine-Weber et al., 2018). Further, 
my work revealed that the expression level of the MERS-CoV receptor DPP4 has an 
impact on the dependence of MERS-S priming at the S2’ site. Thus, cellular entry of 
viral transduction vectors harboring a MERS-S variant with a mutated S2’ site was 
almost at background level for wildtype 293T cells whereas the same S protein 
variant allowed for robust viral entry into 293T cells transiently overexpressing DPP4 
(Kleine-Weber et al., 2018) 




6.1.2. Natural sequence variations in the S protein of MERS-CoV isolates or 
the cellular receptor DPP4 affect viral entry and viral resistance 
against antibody-mediated neutralization 
The efficacy of S protein binding with its cellular receptor can be influenced by 
natural sequence polymorphisms of the S protein. Thus, sequence variations at S 
protein residues directly interacting with residues of the receptor molecule might 
enhance or decrease binding efficiency. The emergence of polymorphic residues in 
coronavirus S proteins can happen spontaneously due to the high mutation rate of 
RNA viruses (Elena and Sanjua, 2005; Duffy, 2018). Alternatively, sequence 
variations can develop as a consequence of a selective pressure. 
During the MERS outbreak in 2015 in the Republic of Korea, which was started by 
single infected traveler returning from the Middle East, two particular polymorphisms 
in the receptor binding domain of MERS-S, D510G and I529T, emerged in several 
patients (Kim et al., 2016). I529T was found in 72% of sequences and was passed 
on during transmission events. In contrast, D510G was less frequent (Kim et al., 
2016). It was further shown, that both polymorphisms were associated with a 
reduced ability of the S protein to bind to DPP4 and polymorphism I529T was shown 
to be less efficient in mediating cellular entry of viral particles (Kim et al., 2016). 
However, besides this “negative” effect for the virus no functional benefit was 
revealed that could be a selective force to drive emergence of these two 
polymorphisms.  
In front of this background, I investigated the consequences of the two Korean 
polymorphisms on S protein-driven host cell entry and evasion of the adaptive 
immune response. I could confirm lower binding efficiency for MERS-S harboring 
either polymorphism D510G or I529T. However, this “defect” was only associated 




with reduced viral entry into target cells expressing low levels of DPP4, whereas for 
cells expressing high amounts of DPP4, S protein-driven entry was as or almost as 
efficient as for wildtype MERS-S (Kleine-Weber et al., 2019). These results indicate 
that infection of target cells expressing high DPP4 levels by MERS-CoV variants 
bearing S protein polymorphisms D510G or I529T would not be compromised. More 
importantly, I revealed that both polymorphisms provided the S protein with some 
resistance against neutralization mediated by antibodies present in sera from MERS 
patients (Kleine-Weber et al., 2019). This observation fits well to the previous study 
by Tang and colleagues who reported that MERS-CoV can acquire mutations that 
can allow the virus to escape from neutralizing antibodies and that these mutations 
could affect receptor binding (Tang et al., 2014).  
In sum, these findings are of high importance for vaccine design, as this suggests 
that MERS-CoV, and likely other (emerging) coronaviruses, could have the potential 
to rapidly escape from neutralizing antibodies that target only a single epitope on the 
S protein. It should therefore be a focus to design vaccines that elicit antibodies 
against multiple epitopes or administer a combination of monoclonal antibodies with 
different targets.  
As mentioned before, DPP4, is highly expressed in the human respiratory tract, 
which has been also reported for ACE2 (Tipnis et al., 2000; Vliegen et al., 2017). 
Besides the presence of sufficient amounts of receptor molecules on the cell surface 
also the efficiency of S protein/receptor-interaction is a key factor that defines 
whether a coronavirus can successfully enter a target cell. The binding efficiency of 
the coronaviral S protein to its respective receptor can be affected by natural-
occurring polymorphisms present in either the S protein or in the receptor molecule, 
especially at the binding interface. Naturally-occurring polymorphisms can be found 




in all proteins. In most cases these polymorphisms are not associated with a 
phenotype for the host, however, in some cases, single nucleotide polymorphisms 
(SNPs) can cause amino acid changes and thereby affect protein function, which 
itself can induce diseases including different types of cancer or metabolic disorders 
(e.g. diabetes) (Böhm et al., 2017; Hoppe et al., 2018). Diabetes, like obesity and 
heart conditions, is an underlying condition (comorbidity) in MERS or COVID-19 
patients that is associated with increased risk for severe disease and mortality 
(Guery et al., 2013; Al-Tawfiq et al., 2014; Memish, Cotten, Watson, et al., 2014; 
Rabeeah et al., 2014; Guan et al., 2020; Guo et al., 2020). The coronavirus receptors 
DPP4 and ACE2 have been shown to be involved in metabolic processes (e.g. 
glucose metabolism, blood pressure regulation) that are often disturbed in patients 
suffering from severe coronavirus infection (Crowley et al., 2005; Demuth, McIntosh 
and Pederson, 2005; Memish, Cotten, Watson, et al., 2014; Guo et al., 2020). DPP4 
plays a crucial role for the glucose metabolism and ACE2 plays an important role on 
the insulin secretion in pancreatic islets and the homeostasis of vascular function 
including the blood pressure (Crowley et al., 2005; Demuth, McIntosh and Pederson, 
2005; Tikellis and Thomas, 2012). Further, polymorphisms in ACE2 have already 
been shown to play a role in systemically arterial hypertension and diabetes (Liu et 
al., 2018; Pinheiro et al., 2019). 
Whether naturally-occurring polymorphism in the MERS-CoV receptor DPP4 may 
have an impact on MERS-S-driven cell entry – and thus susceptibility to MERS-CoV 
infection – had not been investigated before. Therefore, I analyzed natural sequence 
variations in DPP4 at the MERS-S/DPP4 binding interface and found that some of 
them were associated with reduced S protein-driven host cell entry and replication of 
authentic MERS-CoV. Further, I could reveal that this phenotype was caused due to 




a less efficient binding of MERS-S to the respective DPP4 variants (Kleine-Weber et 
al., 2020).  
Based on these findings it would be interesting to expand this kind of study to ACE2 
and to screen MERS and COVID-19 patients for the presence of polymorphisms in 
DPP4 or ACE2, respectively, in order to investigate whether particular 
polymorphisms are associated with mild or severe disease. Further, it could be 
analyzed if particular populations, ethnic groups or people with chronic medical 
conditions possess unique polymorphisms that make them less/higher susceptible to 
infection and/or development of severe disease. A straight-forward study could 
comparatively analyze populations in Africa and the Arabia Peninsula regarding the 
presence and distribution of DPP4 polymorphisms. This would be interesting as the 
vast majority of MERS cases is attributed to Saudi-Arabia while MERS-CoV-positive 
dromedary camels are present through-out the Western and Eastern part of North-
Africa as indicated by several studies (Chu et al., 2014; Müller et al., 2014; Reusken 
et al., 2014; Mohd, Al-Tawfiq and Memish, 2016).  
 
6.1.3. S proteins of MERS-CoV isolates that were recently found in 
dromedary camels in Africa enable efficient viral entry into human 
cells 
Shortly after the emergence of MERS-CoV in 2012 in Saudi-Arabia and the 
identification of dromedary camels as the main source of human infections, several 
studies have shown that also African camels harbor MERS-CoV (Chu et al., 2014; 
Müller et al., 2014; Reusken et al., 2014; Mohd, Al-Tawfiq and Memish, 2016). 
However, although there are ongoing MERS-CoV infections reported for the Arabian 
Peninsula since 2012 (WHO, 2019) only limited evidence has been obtained for 




MERS-CoV infections in humans with camel-contact in Africa (Abbad et al., 2019; 
Kiyong’a et al., 2020; Sayed, Malek and Abushahba, 2020). It was thus speculated 
that MERS-CoV variants present in African dromedaries might differ with respect to 
their potential to infect humans from MERS-CoV variants prevalent in the Arabian 
Peninsula (H. Chu et al., 2018). Moreover, two studies suggest that African camel 
MERS-CoV variants are less efficient in entering and replicating in human cells (H. 
Chu et al., 2018; Shirato et al., 2019). 
In the light of these results, I investigated whether the S proteins from MERS-CoV 
variants circulating in dromedary camels in North- and West-Africa differ in their 
potential to drive viral entry into human cells compared to S proteins from MERS-
CoV variants found in the Middle East. I found out that there were no differences in 
the cellular entry efficiency by viral particles harboring either the prototype Arabian 
MERS-S or S proteins related to MERS-CoV variants from African dromedaries. I 
could further show that all S proteins tested displayed the same potential to bind to 
DPP4 (Kleine-Weber, Pöhlmann and Hoffmann, 2019). A plausible explanation for 
the different findings could be that host cell entry might not be different for African 
and Arabian MERS-CoV variants and that post-entry events are the reason for the 
different extent of human infections in the two regions. Nevertheless, it should also 
be taken into account that it might as well possible that human MERS-CoV infections 
are severely underreported in Africa due to lack of diagnostic tests and/or an 
insufficient capacities in the infrastructure of the health care system in most African 
countries.  




6.2. Identification of ACE2, furin and TMPRSS2 as host cell factors 
required for cellular entry of SARS-CoV-2 
With respect to the novel coronavirus SARS-CoV-2, I participated in a collaborative 
study, which identified ACE2 as the cellular receptor for SARS-CoV-2 and TMPRSS2 
as the cellular protease required for SARS-2-S priming in order to enable infection of 
human lung cells (Hoffmann, Kleine-Weber, et al., 2020). Most importantly, this study 
showed that inhibition of TMPRSS2 provides a promising antiviral therapy and 
identified a clinically-approved TMPRSS2 inhibitor (camostat mesylate) as a potential 
treatment option (Hoffmann, Kleine-Weber, et al., 2020). Like MERS-S, SARS-2-S 
also harbors a multibasic motif at the S1/S2 site, which is different from SARS-S, 
which contains a monobasic motif at the S1/S2 site. With respect to the S2’ site, only 
MERS-S harbors a multibasic motif while SARS-2-S and SARS-S each have 
monobasic motifs at their S2’ sites (Gierer et al., 2013; Reinke et al., 2017; 
Hoffmann, Kleine-Weber, et al., 2020). Based on my findings on the proteolytic 
priming of MERS-S, it was expected that proteolytic priming of SARS-2-S might also 
follow a two-step process, including pre-priming at the S1/S2 site by a protease that 
requires a multibasic motif (e.g. furin) (Nakayama, 1997) and a second priming event 
at the S2’ site involving a protease that requires only a monobasic motif (e.g. 
TMPRSS2) (Kleine-Weber et al., 2018). My work could demonstrate that similar to 
MERS-S, also SARS-2-S undergoes a proteolytic cleavage event in S protein 
expressing cells before a new host cell entry event is started (Hoffmann, Kleine-
Weber and Pöhlmann, 2020; Hoffmann, Kleine-Weber, et al., 2020). Furthermore, I 
was able to verify that SARS-2-S priming at the S1/S2 site is achieved by the cellular 
protease furin and that this pre-cleavage is required for a subsequent priming event 
by TMPRSS2 at the S2’ during host cell entry into human lung cells (Hoffmann, 
Kleine-Weber and Pöhlmann, 2020). 




6.3. Inhibition of S protein priming by the cellular protease TMPRSS2 
provides a strategy for antiviral therapy 
The importance of TMPRSS2-mediated priming of S proteins of human 
coronaviruses suggests that interfering with this step could provide a promising 
strategy for antiviral therapy. Camostat mesylate is a serine protease inhibitor and is 
approved for the treatment of pancreatitis in Japan. Previous work including my own, 
could demonstrate that camostat mesylate-mediated inhibition of TMPRSS2 can 
block MERS-S, SARS-2-S and SARS-S protein-driven host entry into human lung 
(Kleine-Weber et al., 2018; Hoffmann, Kleine-Weber, et al., 2020; Hoffmann, 
Schroeder, et al., 2020). Likewise, it was shown that camostat mesylate also inhibits 
viral replication of authentic MERS-CoV and SARS-CoV-2 in TMPRSS2-positive 
target cells (Kawase et al., 2012; Zhou et al., 2015; Shirato, Kawase and 
Matsuyama, 2018a; Hoffmann, Kleine-Weber, et al., 2020). Besides camostat 
mesylate also other serine protease inhibitors could serve as treatment options for 
patients infected with emerging coronaviruses. In this context, nafamostat mesylate, 
an FDA (U.S. Food and Drug Administration)-approved serine protease inhibitor was 
identified to be highly effective in inhibiting entry driven by the S proteins of SARS-
CoV, SARS-CoV-2 and MERS-CoV as well as replication of authentic SARS-CoV-2 
in human lung cells (Hoffmann, Schroeder, et al., 2020). The ability of nafasmostat 
mesylate to block replication of MERS-CoV has also been demonstrated by others 
(Yamamoto et al., 2016). Although, serine protease inhibitors appear to be promising 
therapeutics against coronavirus infections in vitro data from clinical studies for their 
use as treatment options for patients infected with MERS-CoV or SARS-CoV are 
currently missing.   




It has been claimed that presence or acquisition of a multibasic cleavage site in 
coronavirus S protein, like that found in MERS-S or SARS-2-S, is a crucial factor 
defining the zoonotic potential of animal coronaviruses (Yang et al., 2014; Menachery 
et al., 2019). Analysis of SARS-2-S-related S protein sequences from other 
betacoronaviruses found in bats and other animals revealed that only SARS-2-S 
harbors a multibasic cleavage site at the junction of the S1 and S2 subunits (Coutard 
et al., 2020; Hoffmann, Kleine-Weber, et al., 2020; Jaimes et al., 2020; Walls et al., 
2020). In case of MERS-S it was shown that furin-mediated cleavage at this site 
enables subsequent TMPRSS2-mediated MERS-S priming during host cell entry at 
the S2’ site (Park et al., 2016), as mentioned before. The presence of multi- or 
monobasic motifs might also be important for the disease development as furin is 
ubiquitously expressed, while TMPRSS2 is mainly found in the aerodigestive tract 
(Vaarala et al., 2001). In case of avian IAV, infections of poultry by viruses harboring 
monobasic motifs in their HA are mostly limited to the intestinal and respiratory tract, 
whereas infections by viruses harboring multibasic motifs in their HA can lead to 
systemic viral spread (Luczo et al., 2009; Yang et al., 2014; Menachery et al., 2019).  
Whether the presence of a multibasic motif at the S1/S2 site of SARS-2-S is 
processed by furin in infected cells and whether this proteolytic cleavage is required 
for infection of new target cells and efficient viral spread within the host was so far 
unknown. Using SARS-2-S variants with altered S1/S2 cleavage motifs and protease 
inhibitors I revealed that SARS-2-S is indeed proteolytically processed by the cellular 
protease furin in S protein expressing cells. Moreover, I was able to show that this 
priming event is necessary for subsequent S protein processing by TMPRSS2 and 
efficient viral entry into human lung cells (Hoffmann, Kleine-Weber and Pöhlmann, 
2020). Finally, I also obtained evidence for the potential of SARS-CoV-2 to be spread 




from cell to cell by inducing the fusion of SARS-2-S-expressing cells with neighboring 
cells even in the absence of TMPRSS2, a phenotype that is also observed for 
MERS-S (contains a multibasic motif at the S1/S2 site) but not SARS-S (contains a 
monobasic motif at the S1/S2 site) (Hoffmann, Kleine-Weber and Pöhlmann, 2020). 
This finding could explain why SARS-CoV-2 is efficiently spread among the human 
population, as the virus could initially infect ACE2-expressing cells in the upper 
respiratory tract and subsequently be amplified into his region by inducing cell-cell 
fusion. As a result, high concentrations of virus would be present in the upper 
respiratory tract and could thus be disseminated by coughing or exhaling. 
 
6.4. Concluding remarks 
Receptor engagement and proteolytic priming of the coronaviral S protein are crucial 
events in the entry process of coronaviruses and especially the latter displays a 
potential target for antiviral treatment. The existence of natural polymorphisms in 
both the S proteins of coronaviruses and their respective host cell receptors indicate 
that virus variant- or patient-specific polymorphisms can have an impact on the viral 
infectivity and the host’s susceptibility to infection and (possibly) development of 
severe disease. The different studies presented here, which have been conducted as 
part of my thesis, provide important insights on the proteolytic activation of 
coronavirus S proteins and host cell entry of emerging coronaviruses, and thus might 
help to develop new or improve existing strategies for the design of vaccine and 
antiviral compounds.  
 





Before the beginning of this century, coronaviruses have been largely neglected as 
they were “only” associated with mild, self-resolving upper respiratory tract infections. 
However, since the emergence of SARS-CoV in 2002, the research interest in 
coronaviruses has increased and let to fundamental discoveries in the biology of 
coronaviruses including their replication, the proteolytic activation of their S proteins 
and the zoonotic of human coronaviruses. Recent research studies identified 
important points for the molecular understanding of MERS-CoV and SARS-CoV-2 
and the development of vaccines and antiviral therapeutics. Nevertheless, the 
ongoing SARS-CoV-2 pandemic emphasizes that even today animal coronaviruses 
can spill over from an animal reservoir to the human population and cause 
devastating consequences for our health and economics. Therefore, there is the 
urgent need further increase research capacities on coronaviruses addressing points 
like: 
1) How to develop effective and broadly-active vaccines and therapies against known 
(and presently unknown) coronaviruses? 
2) How and how frequent do animal coronavirus recombine in nature and what kind 
of recombination events can drive the emergence of a zoonotic coronavirus and 
allow the virus to cross the species barriers? 
3) With respect to MERS-CoV, why are some regions like the Middle East are more 
affected than others (Africa) despite similar virus prevalence in dromedary camels?  
4) How can zoonotic coronaviruses escape the human immune response after spill-
over events from an animal reservoir? 
 




Hopefully, this study provides some insights on the proteolytic activation of 
coronavirus S proteins, which might help to design antiviral therapeutics against 
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